Novo Nordisk on new key opportunity: We are going into launch mode

The Danish drug group Novo Nordisk expects to launch the new hope of the company’s pipeline in the US by the beginning of 2018. Launches in Japan and Europe will follow later in the year. According to CEO Lars Fruergaard Jørgensen, the weekly GLP-1 analogue provides Novo with a golden opportunity to take on Trulicity, the rival drug from Eli Lilly.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MSD's Keytruda fejler i mavekræftstudie

Immunterapien Keytruda fra amerikanske Merck/MSD har ikke kunnet overgå kemoterapi i andenlinjebehandling af patienter med kræft i mave eller spiserør. Lægemidlet blev for få måneder siden godkendt i indikationen i tredje linje.

Latest Top picks in English

Related articles